Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.72 |
| ▸ | GHSR | Q92847 | 7/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774683 | 1.00 | SLC15A2 (0.72) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL27706632 | 0.91 | SLC15A2 (0.74) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL30911281 | 0.91 | SLC15A2 (0.74) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL27806351 | 0.89 | CYP3A4 (0.60) | SLC15A2CPB2CYP3A4SLC7A5 | |
| SCHEMBL22217022 | 0.85 | SLC15A2 (0.79) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL30409074 | 0.85 | SLC15A2 (0.71) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL28027302 | 0.85 | SLC15A2 (0.71) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL27687339 | 0.84 | SLC15A2 (0.63) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL30175135 | 0.84 | SLC15A2 (1.00) | SLC15A2GHSRCPB2CYP3A4SLC7A5 | |
| SCHEMBL22462015 | 0.84 | SLC15A2 (1.00) | SLC15A2GHSRCPB2CYP3A4SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777875-B1 | SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS | 3 D MATRIX LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| EP-3548105-B1 | METHOD FOR PRODUCING A PEPTIDE-BASED NANO FIBER STRUCTURE AND A NANO FIBER STRUCTURE THUS OBTAINED | HUMANA MEDICAL S R L (IT) | 2025-03-05 | — | — | EP | disclosed |
| US-12006085-B2 | Fill-finish process for peptide solutions | 3-D MATRIX, LTD. (JP) | 2024-06-11 | — | — | US | disclosed |
| US-11839694-B2 | Compositions and methods for promoting hemostasis and other physiological activities | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230190864-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3-D MATRIX, LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| EP-2283851-B1 | Compositions for promoting hemostasis | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220324601-A1 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | 3-D MATRIX, LTD. (JP) | 2022-10-13 | — | — | US | disclosed |
| EP-4049671-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3D Matrix, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220258900-A9 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | 3-D MATRIX, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| EP-4023240-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3D Matrix, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190864-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | IAPP, NGLY1, VIP | SLC15A2 2391/4885GHSR 3064/4885CPB2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.